Vascular Protection in People with Diabetes

Canadian Journal of Diabetes

Volumn 37, Issue SUPPL.1, 2013, Pages

  Stone, James A ^a   Fitchett, David ^a   Grover, Steven ^a   Lewanczuk, Richard ^a   Lin, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CHOLESTEROL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERINDOPRIL; PLACEBO; RAMIPRIL; RAMIPRILAT; SIMVASTATIN; TELMISARTAN; CARDIOVASCULAR AGENT;

ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DIABETES MELLITUS; DIET THERAPY; DISEASE DURATION; EXERCISE; GASTROINTESTINAL HEMORRHAGE; GLYCEMIC CONTROL; HEALTH BEHAVIOR; HEART INFARCTION; HEART PROTECTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PLATELET REACTIVITY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROTECTION; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; THROMBOCYTE AGGREGATION; THROMBOSIS; VASCULAR PROTECTION; WEIGHT CONTROL; CANADA; RISK;

CANADA; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HEALTH BEHAVIOR; HUMANS; RISK;

EID: 84876029360     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.01.030     Document Type: Article

References (53)

1. Booth G.L., Kapral M.K., Fung K., Tu J.V. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006, 368:29-36.
2. Manuel D.G., Schultz S.E. Health-related quality of life and health-adjusted life expectancy of people with diabetes in Ontario, Canada, 1996-1997. Diabetes Care 2004, 27:407-414.
3. Haffner S.M., Lehto S., Rönnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
4. Stevens R.J., Kothari V., Adler A.I., et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001, 101:671-679.
5. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N Engl J Med 2005, 353:2643-2653. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group.
6. Grover S.A., Lowensteyn I., Esrey K.L., et al. Do doctors accurately assess coronary risk in their patients? preliminary results of the coronary health assessment study. BMJ 1995, 310:975-978.
7. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
8. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and CAD in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
9. Gaede P., Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
10. Stock S., Drabik A., Büscher G., et al. German diabetes management programs improve quality of care and curb costs. Health Affairs 2010, 29:2197-2205.
11. Bergner D.W., Goldberger J.J. Diabetes mellitus and sudden cardiac death: what are the data?. Cardiol J 2010, 17:117-129.
12. Guzder R.N., Gatling W., Mullee M.A., et al. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study. Diabet Med 2005, 22:554-562.
13. Lloyd Jones D.M., Leip E.P., Larson M.G., et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006, 113:791-798.
14. Stone J.A. Framing CVD event risk prediction. Can J Cardiol 2011, 27:171-173.
15. Fox C.S., Pencina M.J., Wilson P.W., et al. Lifetime risk of CAD among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care 2008, 31:1582-1584.
16. Laing S.P., Swerdlow A.J., Slater S.D., et al. The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999, 16:466-471.
17. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group.
18. Schwab K.O., Doerfer J., Hecker W., et al. Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes. Cross-sectional data from the German diabetes documentation and quality management system (DPV). Diabetes Care 2006, 29:218-225. DPV Initiative of the German Working Group for Pediatric Diabetology.
19. Solberg L., Desai J.R., O'Connor P.J., et al. Diabetic patients who smoke: are they different?. Diabetes Care 1999, 22:1887-1898.
20. Haire-Joshu D., Glasgow R.E., Tibbs T.L. American Diabetes Association. Smoking and diabetes. Diabetes Care 2004, 27(suppl 1):S74-S75.
21. Warburton D.E., Nichol C.W., Bredin S.S.D. Health benefits of physical activity: the evidence. CMAJ 2006, 174:801-809.
22. Angiolillo D.J., Suryadevara S. Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Pract Res Clin Endocrinol Metab 2009, 23:375-388.
23. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 2006, 97:38-43.
24. Berger J.S., Roncaglioni M.C., Avanzini F., et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006, 295:306-313.
25. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005, 352:1293-1304.
26. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994, 308:81-106.
27. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992, 268:1292-1300.
28. Ogawa H., Nakayama M., Morimoto T., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008, 300:2134-2141.
29. Belch J., MacCuish A., Campbell I., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008, 337:a1840.
30. Peto R., Gray R., Collins R., et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988, 296:313-316.
31. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755-1762.
32. Sacco M., Pellegrini F., Roncaglioni M.C., et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003, 26:3264-3272.
33. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998, 351:233-241.
34. Baigent C., Blackwell L., Collins R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373:1849-1860.
35. Calvin A.D., Aggarwal N.R., Murad M.H., et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009, 32:2300-2306.
36. de Berardis G., Sacco M., Strippoli G.F., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009, 339:b4531.
37. Zhang C., Sun A., Zhang P., et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2010, 87:211-218.
38. Pignone M., Alberts M.J., Colwell J.A., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010, 33:1395-1402.
39. Derry S., Loke Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000, 321:1183-1187.
40. Bhatt D.L., Marso S.P., Hirsch A.T., et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002, 90:625-628.
41. Bell A.D., Roussin A., Cartier R., et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol 2011, 27(suppl A):S1-S59.
42. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients. New Engl J Med 2000, 342:145-153. The Heart Outcomes Prevention Evaluation Study Investigators.
43. Gerstein H.C., Yusuf S., Mann J.F.E., et al. Effects of ramipril on CAD and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-259. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.
44. Daly C.A., Fox K.M., Remme W.J., et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005, 26:1369-1378.
45. Yusuf S., Teo K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.
46. Fox K.M. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782-788.
47. Verdecchia P., Reboldi G., Angeli F., et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005, 46:386-392.
48. McAlister F.A. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. Eur Heart J 2012, 33:505-514. Renin Angiotensin System Modulator Meta-Analysis Investigators.
49. Leiter L.A., Harris S.B., Lewis G., et al. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008, 32(suppl 1):S107-S114.
50. Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo controlled trial: Heart Protection Study Collaborative Group. Lancet 2003, 361:2005-2016.
51. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
52. Grover S.A., Coupal L., Zowall H., et al. How cost effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?. Diabetes Care 2001, 24:45-50.
53. Anderson T.J., Grégoire J., Hegele R.A., et al. 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol 2013, 29:151-167.